iRadimed Corporation (NASDAQ:IRMD) Receives $120.00 Consensus Target Price from Brokerages

Shares of iRadimed Corporation (NASDAQ:IRMD) have received an average rating of “Buy” from the five brokerages that are covering the company, MarketBeat reports. One analyst has rated the stock with a hold recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $120.00.

IRMD has been the subject of several recent analyst reports. Freedom Capital upgraded iRadimed to a “strong-buy” rating in a research note on Thursday, April 2nd. Weiss Ratings cut iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, May 20th.

Insider Transactions at iRadimed

In other iRadimed news, CEO Roger E. Susi sold 5,000 shares of the business’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $87.51, for a total transaction of $437,550.00. Following the completion of the transaction, the chief executive officer owned 2,175,000 shares of the company’s stock, valued at approximately $190,334,250. The trade was a 0.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 25,000 shares of company stock valued at $2,170,753 in the last quarter. Insiders own 34.60% of the company’s stock.

Institutional Investors Weigh In On iRadimed

A number of hedge funds have recently made changes to their positions in the stock. Quarry LP bought a new position in iRadimed in the 3rd quarter valued at approximately $40,000. Farther Finance Advisors LLC grew its stake in shares of iRadimed by 827.1% during the fourth quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock worth $43,000 after buying an additional 397 shares during the last quarter. Tower Research Capital LLC TRC grew its stake in shares of iRadimed by 191.1% during the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after buying an additional 495 shares during the last quarter. CWM LLC increased its holdings in shares of iRadimed by 19.5% during the fourth quarter. CWM LLC now owns 657 shares of the medical equipment provider’s stock worth $64,000 after buying an additional 107 shares in the last quarter. Finally, USA Financial Formulas acquired a new position in shares of iRadimed during the fourth quarter worth $82,000. 92.34% of the stock is currently owned by institutional investors and hedge funds.

iRadimed Stock Down 0.9%

IRMD stock opened at $94.08 on Thursday. The company’s 50-day moving average price is $93.86 and its two-hundred day moving average price is $95.88. The firm has a market cap of $1.20 billion, a P/E ratio of 51.41 and a beta of 0.90. iRadimed has a 12 month low of $55.11 and a 12 month high of $107.90.

iRadimed (NASDAQ:IRMD) last issued its quarterly earnings results on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.03. The company had revenue of $21.98 million during the quarter, compared to the consensus estimate of $21.32 million. iRadimed had a net margin of 27.36% and a return on equity of 24.48%. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. Equities analysts predict that iRadimed will post 1.52 EPS for the current year.

iRadimed Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, May 29th. Investors of record on Friday, May 15th were paid a $0.20 dividend. The ex-dividend date of this dividend was Friday, May 15th. This represents a $0.80 annualized dividend and a yield of 0.9%. iRadimed’s dividend payout ratio (DPR) is 43.72%.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.